Sotuvning operatsion marjasi: Lyell (LYEL)

Lyell Pharma (LYEL) kompaniyasining korporativ logotipi

Lyell Immunopharma immun hujayralarning charchashini oldini olish orqali qattiq o'smalarga qarshi kurashish uchun T-hujayra terapiyalarini ishlab chiqadi. Operatsion rentabellik ushbu ishlanmalarning moliyaviy ta'sirini ko'rsatadi, bunda 0.00 ko'rsatkichning joriy qiymatini aks ettiradi. Manfiy qiymatlar R&D xarajatlari tufayli umumiy likvidlik tanqisligi bilan bog'liq, ammo hujayralarni yoshartirish bo'yicha noyob patentlar raqobatchilar uchun sezilarli texnologik to'siqni yaratadi.

LYEL: lyell.com Operatsion foyda normasi 04.07.2022 - 20.11.2026

Lyell Immunopharma - tahliliy kesimlar va asosiy koʻrsatkichlar (LYEL)

- kompaniyaning birjadagi kapitallashuv ko'rsatkichlari:
Kompaniyaning asosiy tahlili:LYEL, Lyell Immunopharma, Inc.
Lyell Pharma asosiy tovari

Operatsion marja moliyaviy xarajatlar va soliqlarni hisobga olguncha, asosiy biznes jarayonlaridan foyda olish samaradorligini aks ettiradi. Ushbu ko'rsatkich operatsion daromadning tushumga nisbati sifatida hisoblanadi va modelning xarajatlarga sezgirligini namoyish etadi. Haqiqiy operatsion marjani tahlil qilish aktivlarning ichki rentabelligini baholash imkonini beradi. Lyell Immunopharma (LYEL) uchun keng ko'lamli tadqiqot va ishlanmalar (R&D) xarajatlari tufayli manfiy qiymatlar kutilmoqda. Yuqori likvidlik rezervi va rahbariyatning ilmiy tajribasi joriy operatsion foyda mavjud bo'lmaganiga qaramay, kompaniyaning barqarorligini ta'minlaydi.

Lyell Immunopharma kimlar bilan raqobatlashadi

Sotuvning operatsion marjasi IBRX|IMCR - Operatsion foyda bo'yicha marjinallik|Sotuvning operatsion marjasi JANX (Janux Pharma)|Operatsion foyda koeffitsiyenti RCUS|Operatsion marja ZYME (Zymeworks)|Operatsion foyda normasi TNGX|iovance.com - Operatsion marja|Sotuvning operatsion rentabelligi Immatics Biotechnologies|Xencor, Inc. (XNCR) - Operatsion rentabellik|Compass Therapeutics - Operatsion foyda normasi|REPL (replimune.com) - Operatsion marja|Operatsion marja Innate Pharma SA|Operatsion rentabellik pyxisoncology.com (PYXS)|CGEN: Operatsion foyda marjasi|IO Biotech Inc - Sotuvning operatsion marjasi|sutrobio.com (STRO) - Sotuvning operatsion rentabelligi|INKT - Operatsion rentabellik|werewolftx.com (HOWL) - Sotuvning operatsion marjasi|Immix (IMMX) - Operatsion rentabellik|ALXO (ALX Oncology Holdings) - Operatsion rentabellik|Sotuvning operatsion marjasi CUE|PDS Biotechnology Corporation (PDSB) - Operatsion faoliyat rentabelligi|Operatsion rentabellik Sonnet BioTherapeutics Holdings Inc. (SONN)|Operatsion marja MAIA Biotechnology Inc (MAIA)|Operatsion rentabellik Liminatus Pharma LIMN|Operatsion foyda normasi LVTX|NXTC: Sotuvning operatsion marjasi|leaptx.com - Operatsion foyda koeffitsiyenti|INTS: Operatsion marja|Sensei Biotherapeutics Inc - Operatsion foyda normasi|Sotuvning operatsion marjasi TOVX|Operatsion foyda bo'yicha sotuv rentabelligi GRTS (Gritstone bio, Inc.)|Sotuvning operatsion marjasi KA (kinetabio.com)|NEXI - Sotuvning operatsion rentabelligi|Turnstone Biologics - Sotuvning operatsion marjasi|Operatsion faoliyat rentabelligi Vaccinex Inc. (VCNX)|harpoontx.com - Operatsion marja